Board of Directors
| Dr Robin Congreve, PhD Chairman | Leading NZ international businessman Partner in Oceania and Eastern Group Further Information |
| David Clarke, ME, MBA Executive Director, CEO | Senior positions in healthcare, technology and finance Former CEO, South Auckland Health Further Information |
| Dr Douglas Wilson, MB, ChB, PhD Non-Executive Director | Former SVP, World Head Medical and Regulatory Affairs, Boehringer Inglehim Participated in bringing 10 new drugs to market in USA Further Information |
| Dr Graeme Howie, PhD Non-Executive Director | Former Pfizer New York; Senior exec. Pharmacia 20+ years big pharma drug development expertise Further Information |
| Tom Amos, B. Eng Non-Executive Director | Director, Macquarie Bank (Macquarie Technology Ventures) Further Information |
| Trevor Scott, FCA Non-Executive Director | Leading NZ businessman Chair of Blis and PEBL Further Information |
Management Team
Professor Peter Gluckman, Chief Scientific Officer, MB, DSc, FRSNZ FRS
Rob Turnbull, Chief Financial Officer, BCom, CA
Dr Mike Bickerdike, Group Science Manager, BSc(Hons), PhD
Robyn Murdoch, Chief Development Officer, BSc, MBA
Maggie Scott, Head Clinical Operations, RGON, RGN (UK)
Dr Kathryn Jones, Chief Business Officer, BSc(Hons), PhD, MComLaw(Hons)
Paulina Luczynska, Intellectual Property Manager, MComLaw(Hons)
Dr Greg Thomas, Consultant, BSc(Hons), PhD
Associate Professor John Bass, Consultant, PhD, DSc, FRSNZ
Dr Frank Sieg, Principal Scientist, PhD
Board of Directors
Dr Robin Congreve, LLM, PhD (Chairman)
Dr Congreve was for many years a partner in Russell McVeagh McKenzie Bartleet & Co specialising in taxation and business law. He was subsequently on the Boards of or chaired a number of public and private companies including NZ Railways Corporation, BNZ, Comalco NZ Limited, Lion Nathan Limited and TruTest Limited. He is a principal of Oceania & Eastern Group, a New Zealand private equity group which has provided private equity funding to both Neuren's predecessor companies, NeuronZ and EndocrinZ. Dr Congreve was founding Chairman of the Auckland Medical School Foundation which led to the formation of NeuronZ within the University of Auckland and subsequently to the introduction of private equity into that company and EndocrinZ.
Mr David Clarke, BE (Hons), ME, BBS, MBA (Managing Director and Chief Executive Officer)
David has significant commercial experience, at Director and Managing Director level in Health, IT and Biotechnology and brings strong organisational skills to Neuren. David stepped into the New Zealand health sector in 1991 from a background in engineering, finance, marketing and sales with previous positions in the steel and food industries. For the five years prior to joining Neuren, David was Chief Executive Officer of South Auckland Health Limited, one of the leading clinical and research centres and health providers in New Zealand. This centre specialises in providing tertiary healthcare, teaching and research, has a staff of 4,000 people and revenue of $500 million, centred around a 900-bed hospital - the largest acute surgical hospital in NZ/Australia. David significantly restructured the management and operations of the centre. During his term, he also arranged significant funding for the organisation, in particular overseas debt and other syndicated facilities, and undertook a $200 million capital programme, successfully completed in 2002. David also worked extensively with Neuren's CSO in developing the research and academic capabilities of South Auckland Health Limited. In addition to his current role as Managing Director of Neuren, David is also a director of two privately held companies. David is a Fellow of the New Zealand Institute of Management, a member of the Royal Society and a member of the NZ Institute of Directors.
Dr Douglas Wilson, MB, ChB, PhD (Director and Chief Medical Officer)
Dr Wilson was originally a medical academic with postgraduate experience in Auckland, London, Oxford and Walter and Eliza Hall Institute, Melbourne. He then spent many years in the international pharmaceutical industry, firstly as Senior Vice-President for Boehringer Ingelheim USA. Doug was responsible for all drugs and clinical development and all interactions with the FDA. Dr Wilson then carried these responsibilities worldwide at Boehringer Ingelheim Head Office in Germany. He has overseen multiple drugs at all phases of development including bringing many drugs successfully to the market in the USA. Dr Wilson is now a consultant to the biotechnology sector.
Dr Graeme Howie, BSc (Hons), PhD (Non-Executive Director)
Dr Howie has over 27 years of management experience in the international pharmaceutical industry with a strong and diverse background in research and development, product development, manufacturing and commercial fields. His most recent experience is in recombinant biotech product development and was until December 2004 a senior executive at Pfizer Inc., based in New York. Dr Howie has extensive international experience in technical and commercial due diligence activities, including in-licensing. He also led and was responsible for new delivery route feasibility studies on human growth hormone and has been responsible for the development and registration of various products throughout the USA, Europe, Australia and Asia. Dr Howie was appointed a Director on 4 February 2005.
Mr Tom Amos, BEng (Non-Executive Director)
Mr Amos founded what became one of Australia's leading specialised technology consultancies, Amos Aked Swift (AAS), in 1983. Over the period until he stepped down in 2000 he built AAS into a highly successful, broad based consultancy and new venture business that now operates throughout Asia with offices in Australia, New Zealand and Indonesia. Mr Amos is a Principal of Wave Link Systems Pty Ltd, a Company that invests and assists in technology related areas. The Company has a portfolio of interests and investments spanning the range from start up to mature public companies. Since founding AAS he has been a managing partner, managing director, CEO and director of a number of public and private companies. Mr Amos is a director of Amos Aked Swift (NZ) Limited, FlowCom Limited, Ambertech Limited and Macquarie Technology Ventures Pty Limited. Mr Amos holds a degree in Electrical Engineering from the University of Sydney.
Mr Trevor Scott, BCom, FCA (PP), FNZIM, F Inst D (Non-Executive Director)
Mr Scott is founder of T.D. Scott and Co., an accountancy and consulting firm, which he formed in 1988. Trevor is an experienced advisor to companies across a variety of industries. He serves on numerous corporate boards and is chairman of several, including Pacific Edge Biotechnology Limited, Mercy Hospital Dunedin Limited, Blis Technologies Limited and Arthur Barnett Limited. He is also a director of Hirequip Limited, Scott Technology Limited and ING Property Limited, all of which are listed on the New Zealand Stock Exchange. Mr Scott is a member of the Board of the New Zealand Seed Fund and also chairs the Board of Otago Innovation Limited, which is the commercial arm of the University of Otago.
Management Team
Professor Peter Gluckman, Chief Scientific Officer, MB, DSc, FRSNZ FRS
Professor Gluckman is one of New Zealand's most outstanding scientists. He is a Fellow of the Royal Society (London) of the Institute of Medicine of the National Academy of Science (USA) and holds a Rutherford Medal for Science and Technology by the Council of the Royal Society of New Zealand. He graduated with medals in medicine, pediatrics, obstetrics, psychiatry, therapeutics and community health, then went on to specialise further in pediatrics and endocrinology in Auckland and San Francisco, where he was an Assistant Professor in Pediatrics at UCSF. He established the Research Centre for Developmental Medicine and Biology of the University of Auckland, which was the forerunner to the Liggins Institute. He holds a University Chair in Pediatric and Perinatal Biology and was Dean of Medicine and Health Sciences at the University of Auckland. He is Foundation Director of the Liggins Institute. He is an inventor with 27 patents and patent applications and the author of over 350 refereed papers and the author of over 150 scientific reviews.
Rob Turnbull, Chief Financial Officer, BCom, CA
Rob has been appointed Chief Financial Officer for Neuren, taking over from Peter Bailey who is returning to the UK. Rob was previously CFO at another biotechnology company based in Auckland. He received his professional training from Auckland University and PricewaterhouseCoopers.
Dr Mike Bickerdike, Group Science Manager, BSc(Hons), PhD
Mike joined Neuren in January 2005 as the companies Science Manager. In his role Dr Bickerdike is responsible for Neuren's discovery research projects and for managing all non-clinical development work to enable and support the company's development programs. Dr Bickerdike previously worked for Vernalis Research in the UK, where he held various positions, including research project leader and department director. He brings valuable experience to Neuren in the areas of research strategy, drug discovery and corporate collaborations within the pharmaceutical industry.
Robyn Murdoch, Chief Development Officer, BSc, MBA
Robyn's 23 year career has included positions as Associate Medical Manager (Pfizer Laboratories), Medical Manager (Smith Kline Beecham) and Regulatory Affairs Manager (Eli Lilly). Robyn's last position involved managing a large international Phase III cardiac study for The Medicines Company (17,000 patients over 500 sites in 50 countries). Robyn leads the clinical development programme.
Maggie Scott, Head Clinical Operations, RGON, RGN (UK)
Maggie joins Neuren with over 18 years experience in coordinating and managing clinical trials in New Zealand and globally, working for companies such as Pfizer, Roche, Novartis, Eli Lilley, Proctor & Gamble Pharmaceuticals. In 1992 Maggie established GLCC, an academic research organisation offering the full range of clinical trial services. She is experienced in working with international regulatory agencies, pharma, service suppliers and site personnel to ensure every effort is made to deliver on target. In conjunction with heading up the clinical operations group, Maggie is currently completing an MBA through Henley Management College in the UK.
Dr Kathryn Jones, Chief Business Officer, BSc(Hons), PhD, MComLaw(Hons)
Kathryn studied neuroscience at the University of Otago and completed an honours degree and a PhD for research on Alzheimer's Disease in 1997. She became involved with the Neuren project while working for the Dean of Medicine at the University of Auckland. She has worked for biopharmaceutical companies since mid-2000 and has extensive experience in intellectual property management, patent prosecution, contract negotiation and management and business development in biopharmaceuticals and medical devices.
Paulina Luczynska, Intellectual Property Manager, MComLaw(Hons)
Paulina's specialisation is intellectual property law. Her previous work experience includes work at one of Poland’s top law firms specialising in various aspects of intellectual property law practice and, during her postgraduate degree, research assistantship at the Commercial Law Department of the University of Auckland. She has broad experience in various aspects of IP portfolio development and protection. Paulina has been with the Company since April 2002 and manages contractual, patent and trade-secret aspects of Neuren's portfolio in cooperation with Neuren’s scientists and patent attorneys.
Dr Greg Thomas, Consultant, BSc(Hons), PhD
Greg worked as a Research Fellow at Prince Henry's Institute for Medical Research (Melbourne) and as a scientist at the Centre for Reproduction Biology in Edinburgh. Subsequently, he joined the Division of Neurophysiology, National Institute for Medical Research in London, where he investigated the use of small molecule peptide mimetics in the release of growth hormone. Greg has published over 50 papers and 50 abstracts in the field of neuroendocrinology. Greg joined Neuren in July 2000 as the Team Leader of the Pharmacokinetics and Formulation Group. In 2002 he was promoted to Principal Scientist and joined the Executive Management Group at Neuren as the Science Manager. Greg holds a PhD in Reproductive Neuroendocrinology. Having recently moved to Perth, Western Australia, Greg is now employed as a Consultant to Neuren.
Associate Professor John Bass, Consultant, PhD, DSc, FRSNZ
John was originally trained in research into control of male reproduction at London University. He then worked for 30 years in the field of growth and metabolic endocrinology with particular relevance to farm animals, and growth and development of muscle. During his time in agricultural research as a research group leader for AgResearch Ltd he has managed a number of research units involved in animal behaviour, lactation physiology, production of therapeutic antibodies in milk, and hair and fibre growth. His own research has resulted in him being awarded a DSc from London University and election as a Fellow of the Royal Society of New Zealand.
Dr Frank Sieg, Principal Scientist, PhD
Frank directs in vitro and mechanism of action research at Neuren and is principally responsible for the process of screening and characterising Neuren's compounds. He gained previous scientific experience at Ruhr University, Bochum and Otto-von-Guericke University, Magdeburg in Germany including extensive experience with cellular neurological systems to study traumatic brain injury and the mechanism of action of therapeutic compounds. Frank holds a Master in Zoology and a PhD in Natural Sciences from the Free University of Berlin.
updated 22nd March, 2006
| © Copyright 1996-2019 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |